Merck & Co., Inc. (MRK) – Strong and focused after Organon spin off

in , , on August 21, 2021

Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products. Merck believes the transaction will deliver significant benefits for both Merck and Organon and create value for Merck shareholders.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast.
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
–  Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 40

Release Information

  • Price
    :

    $99.00

  • Released
    :

    August 21, 2021

  • Last Updated
    :

    July 25, 2022